8-K: Azenta Reports Second Quarter Fiscal 2025 Results: Revenue Up 5%, Adjusted EBITDA Margin Improves

Azenta, Inc. announced its second quarter fiscal 2025 results, reporting a 5% increase in revenue and an improved adjusted EBITDA margin.

Summary

• Azenta, Inc. reported its financial results for the second quarter of fiscal year 2025, which ended on March 31, 2025.
• Revenue from continuing operations was $143 million, a 5% increase year-over-year.
• Organic revenue growth was 6% year-over-year.
• Sample Management Solutions revenue reached $80 million, up 8% year-over-year.
• Multiomics revenue was $64 million, a 2% increase year-over-year.
• The company reported a diluted EPS from continuing operations of ($0.40), compared to ($0.29) in the second quarter of fiscal year 2024.
• Total diluted EPS was ($0.88), compared to ($2.47) a year ago.
• Adjusted EBITDA from continuing operations was $14 million, with an adjusted EBITDA margin of 10.0%.
• Non-GAAP diluted EPS was $0.05, compared to $0.06 one year ago.
• The company ended the quarter with $540 million in cash, cash equivalents, restricted cash, and marketable securities.
• Operating cash flow was $14 million, and free cash flow was $7 million.
• Azenta is reiterating its full-year fiscal 2025 guidance, expecting organic revenue growth in the range of 3% to 5% and adjusted EBITDA margin expansion of approximately 300 basis points relative to fiscal 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue and EBITDA margin improved, the company still reported a loss. Management's comments are optimistic, but the financial results are mixed.

Positives

• Revenue increased by 5% year-over-year, indicating business growth.
• Organic revenue growth of 6% suggests strong underlying demand.
• Sample Management Solutions and Multiomics revenues both increased.
• Adjusted EBITDA margin improved significantly, reflecting better operational efficiency.
• The company has a strong cash position, providing financial flexibility.
• Gross margin was 45.9%, up 140 basis points year over year, mainly driven by higher revenue, favorable sales mix and operational efficiencies.
• Operating expenses were down 3% year over year, primarily due to lower research and development expense and the impact of non-recurring intangible asset impairment charges recorded in the same period last year.

Negatives

• Diluted EPS from continuing operations was negative, indicating a loss.
• Non-GAAP Diluted EPS decreased from $0.06 to $0.05 year-over-year.
• Operating loss was $16 million.
• Other income included $4 million of net interest income versus $9.5 million in the prior year period.

Risks

• Uncertainties in global political and economic conditions could impact results.
• Difficulties in obtaining components and materials from suppliers could affect the ability to meet demand.
• Volatility in the life sciences markets could impact the company's performance.
• Price competition and intellectual property disputes pose ongoing risks.

Future Outlook

Azenta expects total organic revenue to grow in the range of 3% to 5% relative to fiscal 2024 and adjusted EBITDA margin expansion to be approximately 300 basis points relative to fiscal 2024.

Management Comments

• We delivered another quarter of strong performance in an evolving and uncertain macroeconomic environment, said John Marotta, President and CEO.
• We have a healthy balance sheet, and strong cash position, which provides optionality to continue investing in our long-term growth plans while maintaining our continued disciplined in capital deployment.
• We remain confident in our positioning and disciplined in how we operate the business while navigating these uncertain times.

Industry Context

Azenta operates in the life sciences industry, providing sample management solutions and multiomics services. The company's performance is influenced by trends in drug development, clinical research, and advanced cell therapies. Competition includes companies offering similar services and products to pharmaceutical, biotech, academic, and healthcare institutions.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing the specific peer group Azenta benchmarks against.
• However, companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies are major players in the life sciences tools and services market.
• Their revenue growth and EBITDA margins are often used as benchmarks.
• Azenta's 5% revenue growth is within a reasonable range compared to some of these larger, more diversified companies, but a more detailed analysis would require a deeper dive into segment-specific performance and market conditions.

Stakeholder Impact

• Shareholders will be interested in the revenue growth and EBITDA margin improvement, but concerned about the net loss.
• Employees may be affected by restructuring and transformation initiatives.
• Customers should see continued investment in products and services.
• Suppliers may experience changes in demand based on the company's performance.

Next Steps

• Azenta management will host a conference call and webcast to discuss the financial results and answer questions.

Key Dates

Keywords

Azenta, financial results, second quarter, fiscal 2025, revenue, EBITDA, sample management, multiomics, life sciences